Bernard Mj Uitdehaag
Overview
Explore the profile of Bernard Mj Uitdehaag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Dam M, Rottgering J, Nauta I, de Jong B, Klein M, Schoonheim M, et al.
Mult Scler
. 2024 Dec;
31(1):93-106.
PMID: 39651765
Background: Literature on the intricate relationship between self-reported and objectively assessed cognitive functioning suggests a discrepancy between self-reported cognitive complaints (SCC) and actual test performance. Objectives: To investigate the interplay...
2.
Toorop A, Wessels M, Boonkamp L, Gelissen L, Hoitsma E, Zeinstra E, et al.
Mult Scler
. 2024 Nov;
30(13):1683-1688.
PMID: 39494701
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs). Objectives:...
3.
van Lierop Z, Wessels M, Lekranty W, Moraal B, Hof S, Hogenboom L, et al.
Mult Scler
. 2024 Oct;
30(13):1620-1629.
PMID: 39420574
Background And Objectives: Serum neurofilament light (sNfL) is a biomarker for neuro-axonal damage in multiple sclerosis (MS). Clinical implementation remains limited. We investigated the impact of implementation on clinical decisions...
4.
Coerver E, Kacar S, Ciccarelli O, Sormani M, Barkhof F, Arnold D, et al.
Mult Scler
. 2024 Sep;
30(10):1296-1308.
PMID: 39245991
Background: Higher age is associated with less inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS). It is unknown whether age itself or disease duration underlies this association. Objectives: This study...
5.
Krijnen E, Kouwenhoven R, Noteboom S, Barkhof F, Uitdehaag B, Klawiter E, et al.
Mult Scler
. 2024 Jun;
30(11-12):1556-1560.
PMID: 38872276
Background: Cortical lesion subtypes' occurrence and distribution across networks may shed light on cognitive impairment (CI) in multiple sclerosis (MS). Methods: In 332 people with MS, lesions were classified as...
6.
Mattiesing R, Kramer E, Strijbis E, Brouwer I, van Schijndel R, Gentile G, et al.
Mult Scler
. 2023 Nov;
30(1):44-54.
PMID: 38018502
Background: Whether the degree of inflammation (and its resolution) and neurodegeneration after treatment initiation predicts disease progression in multiple sclerosis (MS) remains unclear. Objectives: To assess the predictive value of...
7.
Toorop A, van Lierop Z, Gelissen L, Hoitsma E, Zeinstra E, van Rooij L, et al.
J Neurol Neurosurg Psychiatry
. 2023 Nov;
95(5):392-400.
PMID: 37963723
Background: Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension of treatment...
8.
Wessels M, van Lierop Z, Noteboom S, Strijbis E, Heijst J, van Kempen Z, et al.
Mult Scler
. 2023 Aug;
29(10):1229-1239.
PMID: 37530045
Background: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment. Objective: To assess the value of...
9.
Simon S, Nauta I, Hillebrand A, Schoonheim M, Uitdehaag B, van Dam M, et al.
Mult Scler
. 2023 Mar;
29(8):1001-1011.
PMID: 36964707
Background: Suboptimal performance during neuropsychological testing frequently occurs in multiple sclerosis (MS), leading to unreliable cognitive outcomes. Neurophysiological alterations correlate with MS-related cognitive impairment, but studies have not yet considered...
10.
van Lierop Z, Noteboom S, Steenwijk M, van Dam M, Toorop A, van Kempen Z, et al.
Mult Scler
. 2022 Sep;
28(14):2231-2242.
PMID: 36062492
Background: Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegeneration are lacking....